iTeos Therapeutics Inc. (ITOS)
iTeos Therapeutics Statistics
Share Statistics
iTeos Therapeutics has 38.19M shares outstanding. The number of shares has increased by 1.93% in one year.
| Shares Outstanding | 38.19M |
| Shares Change (YoY) | 1.93% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 79.13% |
| Shares Floating | 33.03M |
| Failed to Deliver (FTD) Shares | 37 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.34M, so 3.66% of the outstanding shares have been sold short.
| Short Interest | 1.34M |
| Short % of Shares Out | 3.66% |
| Short % of Float | 4.35% |
| Short Ratio (days to cover) | 2.78 |
Valuation Ratios
The PE ratio is -2.31 and the forward PE ratio is -2.05. iTeos Therapeutics's PEG ratio is -0.43.
| PE Ratio | -2.31 |
| Forward PE | -2.05 |
| PS Ratio | 8.88 |
| Forward PS | 1.1 |
| PB Ratio | 0.53 |
| P/FCF Ratio | -3.11 |
| PEG Ratio | -0.43 |
Enterprise Valuation
iTeos Therapeutics Inc. has an Enterprise Value (EV) of 146.49M.
| EV / Earnings | -1.09 |
| EV / Sales | 4.19 |
| EV / EBITDA | -0.96 |
| EV / EBIT | -0.92 |
| EV / FCF | -1.47 |
Financial Position
The company has a current ratio of 12.62, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.62 |
| Quick Ratio | 12.62 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.86 |
| Cash Flow / Debt | -19.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.23% and return on capital (ROIC) is -29.93%.
| Return on Equity (ROE) | -0.23% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -29.93% |
| Revenue Per Employee | $202,312.14 |
| Profits Per Employee | $-776,959.54 |
| Employee Count | 173 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 14.07M |
| Effective Tax Rate | -0.12 |
Stock Price Statistics
The stock price has increased by -53.67% in the last 52 weeks. The beta is 1.38, so iTeos Therapeutics's price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -53.67% |
| 50-Day Moving Average | 7.28 |
| 200-Day Moving Average | 10.8 |
| Relative Strength Index (RSI) | 34.52 |
| Average Volume (20 Days) | 319.82K |
Income Statement
In the last 12 months, iTeos Therapeutics had revenue of 35M and earned -134.41M in profits. Earnings per share was -3.32.
| Revenue | 35M |
| Gross Profit | 35M |
| Operating Income | -159.53M |
| Net Income | -134.41M |
| EBITDA | -153.09M |
| EBIT | -159.53M |
| Earnings Per Share (EPS) | -3.32 |
Balance Sheet
The company has 142.13M in cash and 5.1M in debt, giving a net cash position of 137.03M.
| Cash & Cash Equivalents | 142.13M |
| Total Debt | 5.1M |
| Net Cash | 137.03M |
| Retained Earnings | -9.78M |
| Total Assets | 686.98M |
| Working Capital | 469.18M |
Cash Flow
In the last 12 months, operating cash flow was -98.18M and capital expenditures -1.63M, giving a free cash flow of -99.81M.
| Operating Cash Flow | -98.18M |
| Capital Expenditures | -1.63M |
| Free Cash Flow | -99.81M |
| FCF Per Share | -2.47 |
Margins
Gross margin is 100%, with operating and profit margins of -455.79% and -384.04%.
| Gross Margin | 100% |
| Operating Margin | -455.79% |
| Pretax Margin | -343.83% |
| Profit Margin | -384.04% |
| EBITDA Margin | -437.39% |
| EBIT Margin | -455.79% |
| FCF Margin | -285.18% |
Dividends & Yields
ITOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -52.53% |
| FCF Yield | -41.35% |
Analyst Forecast
The average price target for ITOS is $17, which is 169% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 169% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 1.69 |
| Piotroski F-Score | 2 |